Cancer stem cells: Perspectives of new therapeutical approaches for breast cancer

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 4, 2011, Pages 1486-1499

  Nicolini, A ^a   Ferrari, P ^a   Fini, M ^b   Borsari, V ^b   Fallahi, P ^a   Antonelli, A ^a   Carpi, A ^c   Miccoli, P ^a  

^a UNIVERSITY OF PISA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c Department of Reproduction and Ageing ^*  (Italy)

Author keywords

Breast cancer; New therapies; Resistance to treatment; Review; Stem cells

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; CYCLOPAMINE; CYTOKERATIN 5; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; GAMMA SECRETASE INHIBITOR; GEFITINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MUCIN 1; NERATINIB; NOTCH RECEPTOR; PERTUZUMAB; PHEOPHORBIDE; PROTEIN KINASE B; RETINOIC ACID; SONIC HEDGEHOG PROTEIN; T LYMPHOCYTE ANTIGEN; TAMOXIFEN; TANESPIMYCIN; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; WNT PROTEIN; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALPHA6 INTEGRIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLOTILLINS; HER2 PROTEIN, HUMAN; ISOENZYME; MEMBRANE PROTEIN; QUINAZOLINE DERIVATIVE; RETINAL DEHYDROGENASE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL THERAPY; CIRCULATING TUMOR CELL; DENDRITIC CELL; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NONHUMAN; SELF CONCEPT; SIGNAL TRANSDUCTION; STEM CELL NICHE; BIOLOGICAL MODEL; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PHYSIOLOGY; REVIEW;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DENDRITIC CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; INTEGRIN ALPHA6; ISOENZYMES; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; MUCIN-1; NEOPLASTIC STEM CELLS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETINAL DEHYDROGENASE; SIGNAL TRANSDUCTION;

EID: 80053124150     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s239     Document Type: Article

References (104)

1. B. Groner, V. Vafaizadeh, B. Brill and P. Klemmt: Mammary epithelial and breast cancer stem cells. Eur J Cancer 45,186-193 (2009)
2. M. Al-Hajj, M.S. Wicha; A. Benito-Hernandez, S.J. Morrison and M.F. Clarke: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983-3988 (2003)
3. K. Polyak: Breast cancer: origins and evolution. J Clin Invest 117, 3155-3163 (2007)
4. J.S. Burns, B.M. Abdallah, P. Guldberg, J. Rygaard, H.D. Schrøder and M. Kassem: Tumorigenic heterogeneity in cancer stem cells evolved from longterm cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res 65, 3126-3135 (2005)
5. G.V. Røsland, A. Svendsen, A. Torsvik, E. Sobala, E. McCormack, H. Immervoll, J. Mysliwietz, J.C. Tonn, R. Goldbrunner, P.E. Lønning, R. Bjerkvig and C. Schichor: Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 69, 5331-5339 (2009)
6. D. Rubio, J. Garcia-Castro, M.C. Martín, R. de la Fuente, J.C. Cigudosa, A.C. Lloyd and A. Bernad: Spontaneous human adult stem cell transformation. Cancer Res 65, 3035-3039 (2005)
7. K. Takahashi and S. Yamanaka: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006)
8. J.C. Lawson, G.L. Blatch and A.L. Edkins: Cancer stem cells in breast cancer and metastasis. Breast Cancer Res Treat 118, 241-254 (2009)
9. S. Liu S, G. Dontu and M.S. Wicha: Mammary stem cells, self-renewal pathways, andcarcinogenesis. Breast Cancer Res 7, 86-95 (2005)
10. G. Honeth, P.O. Bendahl, M. Ringnér, L.H. Saal, S.K. Gruvberger-Saal, K. Lövgren, D. Grabau, M. Fernö, A. Borg and C. Hegardt: The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10, R53 (2008)
11. C.M. Fillmore and C. Kuperwasser: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10, R25 (2008)
12. C.M. Fillmore and C. Kuperwasser: Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res 9, 303 (2007)
13. G. Dontu: Breast cancer stem cell markers - the rocky road to clinical applications. Breast Cancer Res 10, 110 (2008)
14. H.K. Weir, M.J. Thun, B.F. Hankey, L.A. Ries, H.L. Howe, P.A. Wingo, A. Jemal, E. Ward, R.N. Anderson and B.K. Edwards: Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95, 1276-1299 (2003)
15. T.M. Phillips, W.H. McBride and F. Pajonk: The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98, 1777-1785 (2006)
16. M. Dean, T. Fojo and S. Bates: Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284 (2005)
17. B.J. Morrison, C.W. Schmidt, S.R. Lakhani, B.A. Reynolds and J.A. Lopez: Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res 10, 210 (2008)
18. S. Zhou, J.D. Schuetz, K.D. Bunting, A.M. Colapietro, J. Sampath, J.J. Morris, I. Lagutina, G.C. Grosveld, M. Osawa, H. Nakauchi and B.P. Sorrentino: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7, 1028-1034 (2001)
19. R.W. Robey, K. Steadman, O. Polgar, K. Morisaki, M. Blayney, P. Mistry and S.E. Bates: Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64, 1242-1246 (2004)
20. H. Lou and M. Dean: Targeted therapy for cancer stem cells: the patched pathway andABC transporters. Oncogene 26, 1357-1360 (2007)
21. C.H. Yang, C.J. Huang, C.S. Yang, Y.C. Chu, A.L. Cheng, J. Whang-Peng and P.C. Yang: Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65, 6943-6949 (2005)
22. N. Takigawa, M. Takeyama, T. Kozuki, T. Shibayama, A. Hisamoto, K. Kiura, A. Tada, K. Hotta, S. Umemura, K. Ohashi, Y. Fujiwara, S. Takata, E. Ichihara, M. Osawa, M. Tabata, M . Tanimoto and K. Takahashi: Combination of SN- 38 with gefitinib or imatinib overcomes SN-38-resistant smallcell lung cancer cells. Oncol Rep 17, 983-987 (2007)
23. S. Chuthapisith, J. Eremin, M. El-Sheemey and O. Eremin: Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 19, 27-32 (2010)
24. R. Pardal, M.F. Clarke and S.J. Morrison: Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3, 895-902 (2003)
25. S. Liu, G. Dontu, I.D. Mantle, S. Patel, N.S. Ahn, K.W. Jackson, P. Suri and M.S. Wicha: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66, 6063-6071 (2006)
26. C. Massard, E. Deutsch and J.C. Soria: Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 17, 1620-1624 (2006)
27. H. Korkaya and M.S. Wicha: HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 15, 1845-1847 (2009)
28. B.J. Nickoloff, B.A. Osborne and L. Miele: Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22, 6598-6608 (2003)
29. G. Farnie, R.B. Clarke, K. Spence, N. Pinnock, K. Brennan, N.G. Anderson and N.J. Bundred: Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 99, 616-627 (2007)
30. G. Dontu, K.W. Jackson, E. McNicholas, M.J. Kawamura, W.M. Abdallah and M.S. Wicha: Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6, R605-615 (2004)
31. N. Yamaguchi, T. Oyama, E. Ito, H. Satoh, S. Azuma, M. Hayashi, K. Shimizu, R. Honma, Y. Yanagisawa, A. Nishikawa, M. Kawamura, J. Imai, S. Ohwada, K. Tatsuta, J. Inoue, K. Semba and S. Watanabe: NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2- negative human breast cancer cells. Cancer Res 68, 1881-1888 (2008)
32. A. Magnifico, L. Albano, S. Campaner, D. Delia, F. Castiglioni, P. Gasparini, G. Sozzi, E. Fontanella, S. Menard and E. Tagliabue: Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res 15, 2010-2021 (2009)
33. C. Osipo, P. Patel, P. Rizzo, A.G. Clementz, L. Hao, T.E. Golde and L. Miele: ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 27, 5019-5032
34. P. Rizzo, H. Miao, G. D'Souza, C. Osipo, L.L. Song, J. Yun, H. Zhao, J. Mascarenhas, D. Wyatt, G. Antico, L. Hao, K. Yao, P. Rajan, C. Hicks, K. Siziopikou, S. Selvaggi, A. Bashir, D. Bhandari, A. Marchese, U. Lendahl, J.Z. Qin, D.A. Tonetti, K. Albain, B.J. Nickoloff and L. Miele: Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 68, 5226-5235 (2008)
35. M. Kakarala and M.S. Wicha: Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26, 2813-2820 (2008)
36. H.H. Luu, R. Zhang, R.C. Haydon, E. Rayburn, Q. Kang, W. Si, J.K. Park, H. Wang, Y. Peng, W. Jiang and T.C. He: Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets 4, 653-671 (2004)
37. L. Zhou, N. An, R.C. Haydon, Q. Zhou, H. Cheng, Y. Peng, W. Jiang, H.H. Luu, P. Vanichakarn, J.P. Szatkowski, J.Y. Park, B. Breyer, and T.C. He: Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the betacatenin signaling activity. Cancer Lett 193, 161-170 (2003)
38. A.R. Panigrahi, S.E. Pinder, S.Y. Chan, E.C. Paish, J.F. Robertson and I.O. Ellis: The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204, 93-100 (2004)
39. D.J. Rossi, C.H. Jamieson and I.L. Weissman: Stems cells and the pathways to aging and cancer. Cell 132, 681-696 (2008)
40. C.L. Arteaga and C.I. Truica: Challenges inthe development of anti-epidermal growth factor receptor therapies in breast cancer. Semin Oncol 31, 3-8 (2004)
41. M. Sabbah, S. Emami, G. Redeuilh, S. Julien, G. Prévost, A. Zimber, R. Ouelaa, M. Bracke, O. De Wever and C. Gespach: Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 11, 123-151 (2008)
42. A. Moustakas and C.H. Heldin: . Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98, 1512-1520 (2007)
43. N. Sato, T. Yamamoto, Y. Sekine, T. Yumioka, A. Junicho, H. Fuse and T. Matsuda: Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3. Biochem Biophys Res Commun 300, 847-852 (2003)
44. H. Zhang and F. Burrows: Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82, 488-499 (2004)
45. M.V. Powers and P. Workman: Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13, S125-135 (2006)
46. P. Workman: Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10, 47-51 (2004)
47. A. Citri, B.S. Kochupurakkal and Y. Yarden: The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3, 51-60 (2004)
48. A.D. Basso, D.B. Solit, G. Chiosis, B. Giri, P. Tsichlis and N. Rosen: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277, 39858-39866 (2002)
49. A. Rodina, M. Vilenchik, K. Moulick, J. Aguirre, J. Kim, A. Chiang, J. Litz, C.C . Clement, Y. Kang, Y. She, N. Wu, S. Felts, P. Wipf, J. Massague, X. Jiang, J.L. Brodsky, G.W. Krystal and G. Chiosis: Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol 3, 498-507 (2007)
50. F. Burrows, H. Zhang and, A. Kamal: Hsp90 activation and cell cycle regulation. Cell Cycle 3, 1530-1536 (2004)
51. B.G. Yun and R.L. Matts: Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation. Exp Cell Res 307, 212-223 (2005)
52. A. Kamal, L. Thao, J. Sensintaffar, L. Zhang, M.F. Boehm, L.C. Fritz and F.J. Burrows: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410 (2003)
53. D.B. Solit and G. Chiosis. Development and application of Hsp90 inhibitors. Drug Discov Today 13, 38-43 (2008)
54. K. Patel, M. Piagentini, A. Rascher, Z.Q. Tian, G.O. Buchanan, R. Regentin, Z. Hu, C.R. Hutchinson and R. McDaniel: Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition. Chem Biol 11, 1625-1633 (2004)
55. C.M. Sauvageot, J.L. Weatherbee, S. Kesari, S.E. Winters, J. Barnes, J. Dellagatta, N.R. Ramakrishna, C.D. Stiles, A.L. Kung, M.W. Kieran and P.Y. Wen: Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 11, 109-121 (2009)
56. S. Modi, S. Sugarman, A. Stopeck, H. Linden, W. Ma, K. Kersey, R.G. Johnson, A.L. Hannah and C.A. Hudis: Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2- positive metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings J Clin Oncol 26, 1027 (2008)
57. P.L. Bedard, F. Cardoso and M.J. Piccart-Gebhart: Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia 14, 55-66 (2009)
58. N. Sain, B. Krishnan, M.G. Ormerod, A. De Rienzo, W.M. Liu, S.B. Kaye, P. Workman and A.L. Jackman: Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 5, 1197-1208 (2006)
59. R. Zhang, D. Luo, R. Miao, L. Bai, Q. Ge, W.C. Sessa and W. Min: Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24, 3954-3963 (2005)
60. D.B. Solit, A.D. Basso, A.B. Olshen, H.I. Scher and N. Rosen: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63, 2139-2144 (2033)
61. W.B. Pratt: The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Annu Rev Pharmacol Toxicol 37, 297-326 (1977)
62. M.J. Piatelli, C. Doughty and T.C. Chiles: Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes. J Biol Chem 277, 12144-12150 (2002)
63. N. Grammatikakis, J.H. Lin, A. Grammatikakis and P.N. Tsichlis, B.H. Cochran: p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function. Mol Cell Biol 19, 1661-1672 (1999)
64. J.S. Lee, J.E. Gil, J.H. Kim, T.K. Kim, X. Jin, S.Y. Oh, Y.W. Sohn, H.M. Jeon, H.J. Park, J.W. Park, Y.J. Shin, Y.G. Chung, J.B. Lee, S. You and H. Kim: Brain cancer stem-like cell genesis from p53-deficient mouse astrocytes by oncogenic Ras. Biochem Biophys Res Commun 365, 496-502 (2008)
65. R. Ohno, N. Asou and K. Ohnishi: Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 17, 1454-1463 (2003)
66. S.G. Piccirillo, B.A. Reynolds, N. Zanetti, G. Lamorte, E. Binda, G. Broggi, H. Brem, A. Olivi, F. Dimeco and A.L. Vescovi: Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761-765 (2006)
67. E.L. Alarmo, T. Kuukasjärvi, R. Karhu and A. Kallioniemi: A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat 103, 239-246 (2007)
68. P.M. Biava, D. Bonsignorio and M. Hoxha: Cell proliferation curves of different human tumor lines after in vitro treatment with zebrafish embryonic extracts. J Tumor Marker Oncol 16, 195-202 (2001)
69. T. Livraghi, F. Meloni, A. Frosi, S. Lazzaroni, M. Bizzarri, L. Frari and P.M. Biava: Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: an open randomized clinical trial. Oncol Research 15, 399-408 (2005)
70. H.A. Hirsch, D. Iliopoulos, P.N. Tsichlis and K. Struhl: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69, 7507-7511 (2009)
71. J.E. Thompson and C.B. Thompson: Putting the rap on Akt. J Clin Oncol 22, 4217-4226 (2004)
72. X. Li, M.T. Lewis, J. Huang, C. Gutierrez, C.K. Osborne, M.F. Wu, S.G. Hilsenbeck, A. Pavlick, X. Zhang, G.C. Chamness, H. Wong, J. Rosen and J.C. Chang: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100, 672-679 (2008)
73. H. Korkaya, A. Paulson, F. Iovino and M.S. Wicha: HER2 regulates the mammari stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27, 6120-6130 (2008)
74. C.H. Lu, S.L. Wyszomierski, L.M. Tseng, M.H. Sun, K.H. Lan, C.L. Neal, G.B. Mills, G.N. Hortobagyi, F.J. Esteva and D. Yu: Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13, 5883-5888 (2007)
75. F. André, M. Campone, S.A. Hurvitz, L. Vittori, I. Pylvaenaeinen, T. Sahmoud and R.M. O'Regan: Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. ASCO Annual Meeting Proceedings J Clin Oncol 26, 1003 (2008)
76. G.H. Jerusalem, V. Dieras, F. Cardoso, J. Bergh, A. Fasolo, A. Rorive, C. Manlius, I. Pylvaenaeinen, T. Sahmoud and L. Gianni: Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistanceto trastuzumab. ASCO Annual Meeting Proceedings J Clin Oncol 26, 1057 (2008)
77. A.H. Ting, K.M. McGarvey and S.B. Baylin: The cancer epigenome-components and functional correlates. Genes Dev 20, 3215-3231 (2006)
78. S. Mocellin, S. Mandruzzato, V. Bronte, M. Lise and D. Nitti: Part I: Vaccines for solid tumours. Lancet Oncol 5, 681-689 (2004)
79. J. Banchereau and R.M. Steinman: Dendritic cells and the control of immunity. Nature 392, 245-252 (1998)
80. N.B. Ivanova, J.T. Dimos, C. Schaniel, J.A. Hackney, K.A. Moore and I.R. Lemischka: A stem cell molecular signature. Science 298, 601-604 (2002)
81. D.J. Wong, H. Liu, T.W. Ridky, D. Cassarino, E. Segal and H.Y. Chang: Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2, 333-344 (2008)
82. G. Dontu, W.M. Abdallah, J.M. Foley, K.W. Jackson, M.F. Clarke, M.J. Kawamura and M.S. Wicha: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17, 1253-1270 (2003)
83. K.E. Miletti-González, S. Chen, N. Muthukumaran, G.N. Saglimbeni, X. Wu, J. Yang, K. Apolito, W.J. Shih, W.N. Hait and L. Rodríguez- Rodríguez: The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 65, 6660-6667 (2005)
84. J. Stingl, P. Eirew, I. Ricketson, M. Shackleton, F. Vaillant, D. Choi, H.I. Li and C.J. Eaves: Purification and unique properties of mammary epithelial stem cells. Nature 439, 993-997 (2006)
85. M. Shackleton, F. Vaillant, K.J. Simpson, J. Stingl, G.K. Smyth, M.L. Asselin-Labat, L. Wu, G.J. Lindeman and J.E. Visvader: Generation of a functional mammary gland from a single stem cell. Nature 439, 84-88 (2006)
86. K. Engelmann, H. Shen and O.J. Finn: MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res 68, 2419-2426 (2008)
87. M.H. Wright, A.M. Calcagno, C.D. Salcido, M.D. Carlson, S.V. Ambudkar and L. Varticovski : Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10, R10 (2008)
88. M.S. Wicha: Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res 10, 105 (2008)
89. M. Cristofanilli, D.F. Hayes, G.T. Budd, M.J. Ellis, A. Stopeck, J.M. Reuben, G.V. Doyle, J. Matera, W.J. Allard, M.C. Miller, H.A. Fritsche, G.N. Hortobagyi and L.W. Terstappen: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23, 1420-1430 (2005)
90. F.S. Hodi: Cytotoxic T-lymphocyte-associated antigen- 4. Clin Cancer Res 13, 5238-5242 (2007)
91. C. Ginestier, M.H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M.S. Wicha and G. Dontu: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (2007)
92. P.S. Hall and D.A. Cameron: Current perspective - trastuzumab. Eur J Cancer 45, 12-18 (2009)
93. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga and L. Norton: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783-792 (2001)
94. M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Antón, A. Lluch, J, Kennedy, K. O'Byrne, P. Conte, M. Green, C. Ward, K. Mayne and J.M. Extra: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23, 4265-4274 (2005)
95. Z. Pályi-Krekk, M. Barok, J. Isola, M. Tammi, J. Szöllosi and P. Nagy: Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 43, 2423-2433 (2007)
96. H. Bernhard, J. Neudorfer, K. Gebhard, H. Conrad, C. Hermann, J. Nährig, F. Fend, W. Weber, D.H. Busch and C. Peschel: Adoptive transfer of autologous, HER2- specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother 57, 271-280 (2008)
97. B. Thurner, I. Haendle, C. Röder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, E.B. Bröcker, R.M. Steinman, A. Enk, E. Kämpgen and G. Schuler: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190, 1669-1678 (1999)
98. H. Schreiber, T.H. Wu, J. Nachman and W.M. Kast: Immunodominance and tumor escape. Semin Cancer Biol 12, 25-31 (2002)
99. J. Gong, D. Avigan, D. Chen, Z. Wu, S. Koido, M. Kashiwaba and D. Kufe: Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97, 2715-2718 (2000)
100. C. Brisken and S. Duss: Stem cells and the stem cell niche in the breast: an integrated hormonal and developmental perspective. Stem Cell Rev 3, 147-156 (2007)
101. C. Ginestier, S. Liu, M.E. Diebel, H. Korkaya, M. Luo, M. Brown, J. Wicinski, O. Cabaud, E. Charafe- Jauffret, D. Birnbaum, J.L. Guan, G. Dontu and M.S. Wicha: CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120, 485-497 (2010)
102. E. Charafe-Jauffret, C. Ginestier, F. Iovino, J. Wicinski, N. Cervera, P. Finetti, M.H. Hur, M.E. Diebel, F. Monville, J. Dutcher, M. Brown, P. Viens, L. Xerri, F. Bertucci, G. Stassi, G. Dontu, D. Birnbaum and M.S. Wicha: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69, 1302-1313 (2009)
103. B.C. Baguley: Tumor stem cell niches: a new functional framework for the action of anticancer drugs. Recent Pat Anticancer Drug Discov 1, 121-127 (2006)
104. C. Folkins, S. Man, P. Xu, Y. Shaked, D.J. Hicklin and R.S. Kerbel: Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67, 3560-3564 (2007)